Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954886 | 0.91 | MAPT (0.43) | NNMTMAPTGAAALDH1A1KDM4E | |
| SCHEMBL5956248 | 0.86 | NNMT (0.46) | NNMTMAPTGAAALDH1A1KDM4E | |
| SCHEMBL31132848 | 0.84 | NNMT (0.51) | NNMTMAPTGAAKDM4EKMT2A | |
| SCHEMBL4347479 | 0.84 | NNMT (0.51) | NNMTMAPTGAAKDM4EKMT2A | |
| SCHEMBL24553897 | 0.84 | NNMT (0.51) | NNMTMAPTGAAKMT2AMEN1 | |
| SCHEMBL30570813 | 0.84 | NNMT (0.54) | NNMTMAPTGAAALDH1A1KDM4E | |
| SCHEMBL26118926 | 0.84 | NNMT (0.54) | NNMTMAPTGAAALDH1A1KDM4E | |
| SCHEMBL31637984 | 0.83 | GAA (0.41) | NNMTMAPTGAAALDH1A1KDM4E | |
| SCHEMBL4020131 | 0.83 | GAA (0.41) | NNMTMAPTGAAALDH1A1KDM4E | |
| SCHEMBL29551416 | 0.82 | KDM4E (0.44) | NNMTMAPTGAAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4635949-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-118027018-A | Tetrahydrocyclopentyl [ c ] pyrrole methyl ketone derivative, preparation method and application thereof | 江苏恩华药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-109810041-B | Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | NNMT 2450/4885MAPT 2396/4885GAA 2770/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | NNMT 4397/4885MAPT 3672/4885GAA 3939/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | NNMT 3560/4885MAPT 2060/4885GAA 4379/4885 |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | VAPB, VAPA, ADRA1D | NNMT 2450/4885MAPT 2396/4885GAA 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.